kabutan

TAIKO PHARMA, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 8% Increase in The Current Fiscal Year, Resuming Dividends at 3.3 Yen for the First Time in five terms., This Fiscal Year to Increase Dividend by 0.2 Yen

Fri Feb 13, 2026 3:35 pm JST Earnings

4574 TAIKO PHARMACEUTICAL CO., LTD. 【J-GAAP】

Earnings Report

TAIKO PHARMACEUTICAL CO., LTD. <4574> [TSE Prime] announced its financial results after the market closed on February 13th (15:35). The consolidated ordinary profit for the fiscal year ended December 2025 decreased by 29.9% from the previous period to 482 million yen, although it exceeded the initial forecast of 300 million yen. For the fiscal year ending December 2026, the consolidated ordinary profit is expected to grow by 7.9% to 520 million yen. This will be the fourth consecutive term of revenue growth.

At the same time, the company decided to implement a year-end dividend of 3.3 yen for the previous term, which had been previously undecideddividends were reinstated for the first time infive terms., and has decided to increase the dividend this fiscal year to 3.5 yen, an increase of 0.2 yen from the previous fiscal year.

In the most recent three-month period, from October to December (4Q), the consolidated ordinary profit/loss turned to a profit of 157 million yen (compared to a loss of 17 million yen in the same period last year). The operating profit/loss margin drastically improved from -5.7% in the same period last year to 6.2%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 6,120 -1,005 -1,248 -3,611 -76.3 0 Feb 9, 2024 J-GAAP
Dec, 2024 6,292 629 688 898 17.9 0 Feb 13, 2025 J-GAAP
Dec, 2025 6,397 459 482 923 18.4 3.30 Feb 13, 2026 J-GAAP
YoY +1.7% -27.0% -29.9% +2.8% +2.7%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2025 Guidance 6,300 300 300 580 11.5 － Nov 11, 2025 J-GAAP
Dec, 2025 Results 6,397 459 482 923 18.4 3.30 Feb 13, 2026 J-GAAP
Revision Rate +1.5% +53.0% +60.7% +59.1% +59.3%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jan - Jun, 2025 2,412 46 20 279 5.6 0 Aug 8, 2025 J-GAAP
Jan - Jun, 2026 Guidance ー ー ー ー － 0 Feb 13, 2026 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2024 6,292 629 688 898 17.9 0 Feb 13, 2025 J-GAAP
Dec, 2025 6,397 459 482 923 18.4 3.30 Feb 13, 2026 J-GAAP
Dec, 2026 Guidance 7,200 500 520 550 11.0 3.50 Feb 13, 2026 J-GAAP
YoY +12.6% +8.9% +7.9% -40.4% -40.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 1,713 -97 -17 184 3.7 -5.7 Feb 13, 2025 J-GAAP
Jan - Mar, 2025 1,150 44 11 292 5.8 3.8 May 9, 2025 J-GAAP
Apr - Jun, 2025 1,262 2 9 -13 -0.3 0.2 Aug 8, 2025 J-GAAP
Jul - Sep, 2025 1,817 278 305 390 7.8 15.3 Nov 11, 2025 J-GAAP
Oct - Dec, 2025 2,168 135 157 254 5.1 6.2 Feb 13, 2026 J-GAAP
YoY +26.6% － － +38.0% +37.9%

Related Articles